Why nanodiamond carriers manage to overcome drug resistance in cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F20%3A00537120" target="_blank" >RIV/61388971:_____/20:00537120 - isvavai.cz</a>
Result on the web
<a href="https://cdrjournal.com/article/view/3691" target="_blank" >https://cdrjournal.com/article/view/3691</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.20517/cdr.2020.52" target="_blank" >10.20517/cdr.2020.52</a>
Alternative languages
Result language
angličtina
Original language name
Why nanodiamond carriers manage to overcome drug resistance in cancer
Original language description
Nanodiamonds represent an attractive potential carrier for anticancer drugs. The main advantages of nanodiamond particles with respect to medical applications are their high compatibility with non-cancerous cells, feasible surface decoration with therapeutic and cancer-cell targeting molecules, and their relatively low manufacturing cost. Additionally, nanodiamond carriers significantly increase treatment efficacy of the loaded drug, so anticancer drugs execute more effectively at a lower dose. Subsequently, lower drug dose results in less extensive side effects. The carriers decorated with a targeting molecule accumulate primarily in the tumor tissue, and those nanodiamond particles impair efflux of the drug from cancer cells. Therapeutic approaches considering nanodiamond carriers were already tested in vitro, as well as in vivo. Now, researchers focus particularly on the possible side effects of nanodiamond carriers applied systemically in vivo. The behavior of nanodiamond carriers depends heavily on their surface coatings, so each therapeutic complex must be evaluated separately. Generally, it seems that site-specific application of nanodiamond carriers is a rather safe therapeutic approach, but intravenous application needs further study. The benefits of nanodiamond carriers are remarkable and represent a potent approach to overcome the drug resistance of many cancers.
Czech name
—
Czech description
—
Classification
Type
J<sub>ost</sub> - Miscellaneous article in a specialist periodical
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer Drug Resistance
ISSN
2578-532X
e-ISSN
—
Volume of the periodical
3
Issue of the periodical within the volume
October 2020
Country of publishing house
US - UNITED STATES
Number of pages
13
Pages from-to
854-866
UT code for WoS article
—
EID of the result in the Scopus database
—